Skip to main content
Erschienen in: Tumor Biology 7/2014

01.07.2014 | Research Article

Evaluation of thyroid cancer in Chinese females with breast cancer by vascular endothelial growth factor (VEGF), microvessel density, and contrast-enhanced ultrasound (CEUS)

verfasst von: Xi Wei, Ying Li, Sheng Zhang, Gao Ming

Erschienen in: Tumor Biology | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

To evaluate thyroid cancer in Chinese females with breast cancer by VEGF, MVD, and contrast-enhanced ultrasound (CEUS), 34 of 2,278 female inpatients with breast diseases who underwent routine thyroid ultrasonography were pathologically proved as thyroid cancer and enrolled into two groups: a breast cancer group and a non-breast cancer group. CEUS was performed and enhancement patterns were classified. Time-intensity curve parameters were analyzed to correlate with MVD CD34 and VEGF expression. Fourteen (2.6 %) and 20 (1.1 %) patients in breast cancer and non-breast cancer group were pathologically diagnosed as thyroid cancer. Six (42.8 %) and 0(0 %) patients showed high enhancement CEUS patterns of thyroid cancer in these two groups, respectively. The arrival time of time-intense curve was shorter, and the mean and peak intensity were higher in thyroid cancer in breast cancer group. The mean MVD counts and VEGF expression were significantly higher in thyroid and breast carcinomas in breast cancer group (P < 0.01). We also found that the mean and peak intensity were significantly associated with MVD counts and VEGF expression (P < 0.01). CEUS is recommended in evaluating the microcirculation of thyroid cancer in women with breast cancer and has the significant relationship with MVD counts and VEGF expression.
Literatur
1.
Zurück zum Zitat Wei X, Li Y, Zhu Y, Zhang S. Microvascular of breast lesions evaluated by contrast enhancement ultrasound imaging combined with pathologic basis of angiogenesis. Chin J Clinicians. 2011;5:120–4. article in Chinese. Wei X, Li Y, Zhu Y, Zhang S. Microvascular of breast lesions evaluated by contrast enhancement ultrasound imaging combined with pathologic basis of angiogenesis. Chin J Clinicians. 2011;5:120–4. article in Chinese.
2.
Zurück zum Zitat Wei X, Li Y, Zhang S, Zhu Y, Fan Y. Experience in large-core needle biopsy in the diagnosis of 1431 breast lesions. Med Oncol. 2011;28:429–33.CrossRefPubMed Wei X, Li Y, Zhang S, Zhu Y, Fan Y. Experience in large-core needle biopsy in the diagnosis of 1431 breast lesions. Med Oncol. 2011;28:429–33.CrossRefPubMed
3.
Zurück zum Zitat Eden K, Mahon S, Helfand M. Screening high-risk populations for thyroid cancer. Med Pediatr Oncol. 2001;36:583–91.CrossRefPubMed Eden K, Mahon S, Helfand M. Screening high-risk populations for thyroid cancer. Med Pediatr Oncol. 2001;36:583–91.CrossRefPubMed
4.
Zurück zum Zitat Hardefeldt PJ, Eslick GD, Edirimanne S. Benign thyroid disease is associated with breast cancer: a meta-analysis. Breast Cancer Res Treat. 2012;133:1169–77.CrossRefPubMed Hardefeldt PJ, Eslick GD, Edirimanne S. Benign thyroid disease is associated with breast cancer: a meta-analysis. Breast Cancer Res Treat. 2012;133:1169–77.CrossRefPubMed
5.
Zurück zum Zitat Nio Y, Iguchi C, Itakura M, et al. High incidence of synchronous or metachronous breast cancer in patients with malignant and benign thyroid tumor or tumor-like disorders. Anticancer Res. 2009;29:1607–10.PubMed Nio Y, Iguchi C, Itakura M, et al. High incidence of synchronous or metachronous breast cancer in patients with malignant and benign thyroid tumor or tumor-like disorders. Anticancer Res. 2009;29:1607–10.PubMed
6.
Zurück zum Zitat de Gonzalez Berrington A, Curtis RE, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 2011;12:353–60.CrossRef de Gonzalez Berrington A, Curtis RE, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 2011;12:353–60.CrossRef
7.
Zurück zum Zitat Houtzager S, Wijkstra H, de la Rosette JJ, Laguna MP. Evaluation of renal masses with contrast-enhanced ultrasound. Curr Urol Rep. 2013;14:116–23.CrossRefPubMed Houtzager S, Wijkstra H, de la Rosette JJ, Laguna MP. Evaluation of renal masses with contrast-enhanced ultrasound. Curr Urol Rep. 2013;14:116–23.CrossRefPubMed
8.
Zurück zum Zitat Amarteifio E, Krix M, Wormsbecher S, et al. Dynamic contrast-enhanced ultrasound for assessment of therapy effects on skeletal muscle microcirculation in peripheral arterial disease: pilot study. Eur J Radiol. 2012;82:640–6.CrossRefPubMed Amarteifio E, Krix M, Wormsbecher S, et al. Dynamic contrast-enhanced ultrasound for assessment of therapy effects on skeletal muscle microcirculation in peripheral arterial disease: pilot study. Eur J Radiol. 2012;82:640–6.CrossRefPubMed
9.
Zurück zum Zitat Dănilă M, Sporea I, Sirli R, Popescu A, Sendroiu M, Martie A. The role of contrast enhanced ultrasound (CEUS) in the assessment of liver nodules in patients with cirrhosis. Med Ultrason. 2010;12:145–9.PubMed Dănilă M, Sporea I, Sirli R, Popescu A, Sendroiu M, Martie A. The role of contrast enhanced ultrasound (CEUS) in the assessment of liver nodules in patients with cirrhosis. Med Ultrason. 2010;12:145–9.PubMed
10.
Zurück zum Zitat Xia Y, Jiang YX, Dai Q, Xiao Y, Lv K, Wang L. Contrast-enhanced ultrasound of hepatocellular carcinoma: correlation of washout time and angiogenesis. Clin Hemorheol Microcirc. 2011;48:265–73.PubMed Xia Y, Jiang YX, Dai Q, Xiao Y, Lv K, Wang L. Contrast-enhanced ultrasound of hepatocellular carcinoma: correlation of washout time and angiogenesis. Clin Hemorheol Microcirc. 2011;48:265–73.PubMed
11.
Zurück zum Zitat Uller W, Jung EM, Hornung M, et al. Evaluation of the microvascularization of pathologic parathyroid glands in patients with primary hyperparathyroidism using conventional ultrasound and contrast-enhanced ultrasound. Clin Hemorheol Microcirc. 2011;48:95–103.PubMed Uller W, Jung EM, Hornung M, et al. Evaluation of the microvascularization of pathologic parathyroid glands in patients with primary hyperparathyroidism using conventional ultrasound and contrast-enhanced ultrasound. Clin Hemorheol Microcirc. 2011;48:95–103.PubMed
12.
Zurück zum Zitat Lee SH, Lee SJ, Jin SM, et al. Relationships between lymph node metastasis and expression of CD31, D2-40, and vascular endothelial growth factors A and C in papillary thyroid cancer. Clin Exp Otorhinolaryngol. 2012;5:150–5.PubMedCentralCrossRefPubMed Lee SH, Lee SJ, Jin SM, et al. Relationships between lymph node metastasis and expression of CD31, D2-40, and vascular endothelial growth factors A and C in papillary thyroid cancer. Clin Exp Otorhinolaryngol. 2012;5:150–5.PubMedCentralCrossRefPubMed
13.
Zurück zum Zitat Capp C, Wajner SM, Siqueira DR, Brasil BA, Meurer L, Maia AL. Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2 in medullary thyroid carcinoma. Thyroid. 2010;20:863–71.CrossRefPubMed Capp C, Wajner SM, Siqueira DR, Brasil BA, Meurer L, Maia AL. Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2 in medullary thyroid carcinoma. Thyroid. 2010;20:863–71.CrossRefPubMed
14.
Zurück zum Zitat Jebreel A, England J, Bedford K, Murphy J, Karsai L, Atkin S. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol. 2007;88:271–7.PubMedCentralCrossRefPubMed Jebreel A, England J, Bedford K, Murphy J, Karsai L, Atkin S. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol. 2007;88:271–7.PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat Saponaro C, Malfettone A, Ranieri G, et al. VEGF, HIF-1α Expression and MVD as an angiogenic network in familial breast cancer. PLoS One. 2013;8:e53070.PubMedCentralCrossRefPubMed Saponaro C, Malfettone A, Ranieri G, et al. VEGF, HIF-1α Expression and MVD as an angiogenic network in familial breast cancer. PLoS One. 2013;8:e53070.PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Vassilopoulou-Sellin R, Palmer L, Taylor S, Cooksley CS. Incidence of breast carcinoma in women with thyroid carcinoma. Cancer. 1999;85:696–705.CrossRefPubMed Vassilopoulou-Sellin R, Palmer L, Taylor S, Cooksley CS. Incidence of breast carcinoma in women with thyroid carcinoma. Cancer. 1999;85:696–705.CrossRefPubMed
18.
Zurück zum Zitat Chen AY, Levy L, Goepfert H, Brown BW, Spitz MR. Vassilopoulou-Sellin R. The development of breast carcinoma in women with thyroid carcinoma. Cancer. 2001;92:225–31.CrossRefPubMed Chen AY, Levy L, Goepfert H, Brown BW, Spitz MR. Vassilopoulou-Sellin R. The development of breast carcinoma in women with thyroid carcinoma. Cancer. 2001;92:225–31.CrossRefPubMed
19.
Zurück zum Zitat Park JS, Oh KK, Kim EK, Chang HS, Hong SW. Sonographic screening for thyroid cancer in females undergoing breast sonography. AJR Am J Roentgenol. 2006;186:1025–8.CrossRefPubMed Park JS, Oh KK, Kim EK, Chang HS, Hong SW. Sonographic screening for thyroid cancer in females undergoing breast sonography. AJR Am J Roentgenol. 2006;186:1025–8.CrossRefPubMed
22.
Zurück zum Zitat Cenqiz O, Bozkurt B, Unal B, et al. The relationship between prognostic factors of breast cancer and thyroid disorders in Turkish women. J Surg Oncol. 2004;87:19–25.CrossRef Cenqiz O, Bozkurt B, Unal B, et al. The relationship between prognostic factors of breast cancer and thyroid disorders in Turkish women. J Surg Oncol. 2004;87:19–25.CrossRef
23.
Zurück zum Zitat Grani G, Dicorato P, Dainelli M, et al. Thyroid diseases in women with breast cancer. Clin Ter. 2012;163:e401–4.PubMed Grani G, Dicorato P, Dainelli M, et al. Thyroid diseases in women with breast cancer. Clin Ter. 2012;163:e401–4.PubMed
24.
Zurück zum Zitat Bartolotta TV, Midiri M, Galia M, et al. Qualitative and quantitative evaluation of solitary thyroid nodules with contrast-enhanced ultrasound: initial results. Eur Radiol. 2006;16:2234–41.CrossRefPubMed Bartolotta TV, Midiri M, Galia M, et al. Qualitative and quantitative evaluation of solitary thyroid nodules with contrast-enhanced ultrasound: initial results. Eur Radiol. 2006;16:2234–41.CrossRefPubMed
25.
Zurück zum Zitat Zhang B, Jiang YX, Liu JB, et al. Utility of contrast-enhanced ultrasound for evaluation of thyroid nodules. Thyroid. 2010;20:51–7.CrossRefPubMed Zhang B, Jiang YX, Liu JB, et al. Utility of contrast-enhanced ultrasound for evaluation of thyroid nodules. Thyroid. 2010;20:51–7.CrossRefPubMed
26.
Zurück zum Zitat Nemec U, Nemec SF, Novotny C, Weber M, Czerny C, Krestan CR. Quantitative evaluation of contrast-enhanced ultrasound after intravenous administration of a microbubble contrast agent for differentiation of benign and malignant thyroid nodules: assessment of diagnostic accuracy. Eur Radiol. 2012;22:1357–65.CrossRefPubMed Nemec U, Nemec SF, Novotny C, Weber M, Czerny C, Krestan CR. Quantitative evaluation of contrast-enhanced ultrasound after intravenous administration of a microbubble contrast agent for differentiation of benign and malignant thyroid nodules: assessment of diagnostic accuracy. Eur Radiol. 2012;22:1357–65.CrossRefPubMed
27.
Zurück zum Zitat Huang SM, Lee JC, Wu TJ, Chow NH. Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World J Surg. 2001;25:302–6.CrossRefPubMed Huang SM, Lee JC, Wu TJ, Chow NH. Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World J Surg. 2001;25:302–6.CrossRefPubMed
28.
Zurück zum Zitat Ramsden JD. Angiogenesis in the thyroid gland. J Endocrinol. 2000;66:475–80.CrossRef Ramsden JD. Angiogenesis in the thyroid gland. J Endocrinol. 2000;66:475–80.CrossRef
29.
Zurück zum Zitat Karpanen T, Egeblad M, Karkkainen MJ, et al. Vascular endo-thelial growth factor C promotes tumor lymphjangiogenesis and intralymphatic tumor growth. Cancer Res. 2001;61:1786–90.PubMed Karpanen T, Egeblad M, Karkkainen MJ, et al. Vascular endo-thelial growth factor C promotes tumor lymphjangiogenesis and intralymphatic tumor growth. Cancer Res. 2001;61:1786–90.PubMed
30.
Zurück zum Zitat Lewy-Trenda I, Wierzchniewska-Lawska A. Expression of vascular endothelial growth factor (VEGF) in human thyroid tumor. Pol J Pathol. 2002;53:129–32.PubMed Lewy-Trenda I, Wierzchniewska-Lawska A. Expression of vascular endothelial growth factor (VEGF) in human thyroid tumor. Pol J Pathol. 2002;53:129–32.PubMed
31.
Zurück zum Zitat Fenton C, Patel A, Dinauer C, Robie DK, Tuttle RM, Francis GL. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid. 2000;10:349–57.CrossRefPubMed Fenton C, Patel A, Dinauer C, Robie DK, Tuttle RM, Francis GL. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid. 2000;10:349–57.CrossRefPubMed
Metadaten
Titel
Evaluation of thyroid cancer in Chinese females with breast cancer by vascular endothelial growth factor (VEGF), microvessel density, and contrast-enhanced ultrasound (CEUS)
verfasst von
Xi Wei
Ying Li
Sheng Zhang
Gao Ming
Publikationsdatum
01.07.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 7/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1868-2

Weitere Artikel der Ausgabe 7/2014

Tumor Biology 7/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.